CN102274260B - 一种三七提取物的药物组合物及其制备方法 - Google Patents
一种三七提取物的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN102274260B CN102274260B CN 201110226352 CN201110226352A CN102274260B CN 102274260 B CN102274260 B CN 102274260B CN 201110226352 CN201110226352 CN 201110226352 CN 201110226352 A CN201110226352 A CN 201110226352A CN 102274260 B CN102274260 B CN 102274260B
- Authority
- CN
- China
- Prior art keywords
- extract
- radix notoginseng
- notoginseng
- saponins
- flavones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 179
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 179
- 239000000284 extract Substances 0.000 title claims abstract description 178
- 238000002360 preparation method Methods 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title abstract description 8
- 238000000605 extraction Methods 0.000 title description 4
- 229930003944 flavone Natural products 0.000 claims abstract description 62
- 235000011949 flavones Nutrition 0.000 claims abstract description 62
- 150000002213 flavones Chemical class 0.000 claims description 57
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 53
- 239000000243 solution Substances 0.000 claims description 50
- 230000001476 alcoholic effect Effects 0.000 claims description 31
- 239000003480 eluent Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000002347 injection Methods 0.000 claims description 23
- 239000007924 injection Substances 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 11
- 239000012467 final product Substances 0.000 claims description 11
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 239000012567 medical material Substances 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 238000004809 thin layer chromatography Methods 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 7
- 241000628997 Flos Species 0.000 claims description 4
- 230000000274 adsorptive effect Effects 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000000890 drug combination Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 abstract description 9
- 150000007949 saponins Chemical class 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 5
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 31
- 229940090044 injection Drugs 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 230000003727 cerebral blood flow Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000002490 cerebral effect Effects 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 206010000117 Abnormal behaviour Diseases 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000000916 dilatatory effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 208000037906 ischaemic injury Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 239000009277 Panax notoginseng extract Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000009692 xuesetong Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110226352 CN102274260B (zh) | 2011-08-09 | 2011-08-09 | 一种三七提取物的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110226352 CN102274260B (zh) | 2011-08-09 | 2011-08-09 | 一种三七提取物的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102274260A CN102274260A (zh) | 2011-12-14 |
CN102274260B true CN102274260B (zh) | 2013-04-10 |
Family
ID=45100206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110226352 Active CN102274260B (zh) | 2011-08-09 | 2011-08-09 | 一种三七提取物的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102274260B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103251541B (zh) * | 2013-05-30 | 2016-01-13 | 云南七丹药业股份有限公司 | 一种含三七皂苷的洗发水及其制备方法 |
CN105311077A (zh) * | 2015-11-17 | 2016-02-10 | 李纯 | 一种三七红籽精油 |
CN106983799A (zh) * | 2017-05-25 | 2017-07-28 | 山东大学第二医院 | 一种治疗中心静脉留置导管管口周围的肉芽组织增生的药物组合物 |
CN108835639A (zh) * | 2018-08-07 | 2018-11-20 | 玉溪市维和维生堂保健食品有限公司 | 一种三七花枝组合物及其制备方法与应用 |
CN113116949A (zh) * | 2020-01-15 | 2021-07-16 | 四川森科制药有限公司 | 一种三七总皂苷的提取工艺 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1200916C (zh) * | 2002-11-13 | 2005-05-11 | 吉林省中医中药研究院 | 三七叶中总皂苷和黄酮提取物的制备方法 |
CN1762400A (zh) * | 2004-09-24 | 2006-04-26 | 贵阳云岩西创药物科技开发有限公司 | 血塞通制剂及其制备方法 |
-
2011
- 2011-08-09 CN CN 201110226352 patent/CN102274260B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1200916C (zh) * | 2002-11-13 | 2005-05-11 | 吉林省中医中药研究院 | 三七叶中总皂苷和黄酮提取物的制备方法 |
CN1762400A (zh) * | 2004-09-24 | 2006-04-26 | 贵阳云岩西创药物科技开发有限公司 | 血塞通制剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
张志信 * |
等.三七茎叶中叶苷及黄酮的同步分离工艺研究.《时珍国医国药》.2010,第21卷(第5期),1139-1141. * |
Also Published As
Publication number | Publication date |
---|---|
CN102274260A (zh) | 2011-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101829170A (zh) | 一种三七总皂苷提取物及其制备方法 | |
CN102274260B (zh) | 一种三七提取物的药物组合物及其制备方法 | |
CN101596222A (zh) | 一种精制银杏叶提取物、粉针及其制备方法 | |
WO2006063515A1 (fr) | Utilisation de radix sanguisorbae et de son extrait pour la preparation d’un medicament visant a accroitre la numeration erythrocytaire et le taux d’hemoglobine | |
CN103006838A (zh) | 一种治疗心脑血管疾病的中药组合物 | |
CN101119740A (zh) | 中药地榆及其提取物在制备升高红细胞和血红蛋白药物中的应用 | |
CN102526147B (zh) | 一种三七总皂苷的纯化方法及其制剂 | |
CN103006769A (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
WO2007059685A1 (fr) | Calycosine d'astragalus a fonction de resistance contre le coxackievirus | |
CN100484557C (zh) | 一种治疗心肌缺血、改善微循环的中药复方制剂及其制备方法 | |
CN100509010C (zh) | 一种治疗心脑血管病的中药制剂及其制备方法 | |
CN100509009C (zh) | 一种治疗心脑血管病、缺血性中风的中药制剂及其制备方法 | |
CN109528782A (zh) | 银杏叶提取物作为增效剂在制备对睡眠障碍疾病具有治疗或保健的药物的应用 | |
CN101974011B (zh) | 一种具有药用活性的新化合物灯盏细辛酸甲酯 | |
CN104435045A (zh) | 一种治疗中风及其后遗症的中药组合物及其制备方法 | |
CN105640970B (zh) | 人参茎叶有效部位及其制备方法和应用 | |
CN102716231B (zh) | 一种治疗脑损伤和脑水肿的中药组合物及其应用 | |
CN100418534C (zh) | 一种治疗心脑血管疾病的中药有效部位复方制剂及其制备方法 | |
CN100450496C (zh) | 一种治疗心脑血管疾病的三七和红花复方制剂 | |
CN101974012B (zh) | 一种具有药用活性的新化合物灯盏细辛酸乙酯 | |
CN1899352B (zh) | 一种益气复脉的中药有效部位组合物 | |
CN101974010B (zh) | 一种具有药用活性的新化合物灯盏细辛酸 | |
CN101884660A (zh) | 一种治疗心脑血管疾病的中药组合物及其制法、用途 | |
CN101884666A (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法和用途 | |
CN102293984A (zh) | 一种醒脑静冻干速释制剂及其制备方法与用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal composition of notoginseng root extract and preparation method thereof Effective date of registration: 20191125 Granted publication date: 20130410 Pledgee: Shenyang Shengjing Financing Guarantee Co., Ltd Pledgor: Beijing Zhonghaikang Medical Technology Development Co., Ltd. Registration number: Y2019210000016 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201201 Granted publication date: 20130410 Pledgee: Shenyang Shengjing Financing Guarantee Co.,Ltd. Pledgor: BEIJING ZHONGHAIKANG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Registration number: Y2019210000016 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A pharmaceutical composition of Panax notoginseng extract and its preparation method Effective date of registration: 20201202 Granted publication date: 20130410 Pledgee: Shenyang Shengjing Financing Guarantee Co.,Ltd. Pledgor: BEIJING ZHONGHAIKANG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Registration number: Y2020210000066 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211011 Granted publication date: 20130410 Pledgee: Shenyang Shengjing Financing Guarantee Co.,Ltd. Pledgor: BEIJING ZHONGHAIKANG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Registration number: Y2020210000066 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |